GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The investigators plan to explore the effects of acute pre-treatment with the glucagon like
peptide-1 (GLP-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and
behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment
seeking users of the drug. Additionally, the investigators plan to explore the effects of
sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g.,
euphoric) and behavioral (self-administration) effects of cocaine in experienced,
non-treatment seeking users of the drug.